What is the recommended diagnostic workup for suspected endometrial cancer in a perimenopausal woman presenting with abnormal uterine bleeding?

Diagnostic Workup for Suspected Endometrial Cancer in Perimenopausal Women with Abnormal Uterine Bleeding

Begin with transvaginal ultrasound (TVUS) combined with transabdominal ultrasound and Doppler imaging as your initial diagnostic test, followed immediately by endometrial biopsy if the endometrium is thickened or if bleeding persists regardless of ultrasound findings. 1

Initial Imaging Approach

Transvaginal ultrasound is the first-line imaging modality for perimenopausal women presenting with abnormal uterine bleeding. 1 The ACR Appropriateness Criteria (2020) clearly designates combined transabdominal and transvaginal ultrasound with Doppler as "usually appropriate" for initial evaluation. 1

Critical Imaging Thresholds

Unlike postmenopausal women where an endometrial thickness <4mm has nearly 100% negative predictive value for cancer 1, there is no validated absolute upper limit cutoff for endometrial thickness in premenopausal women. 1 This is a crucial distinction—endometrial thickness varies with menstrual cycle phase in perimenopausal women, and even thin endometrium can harbor polyps or focal pathology. 1

Common pitfall: Do not rely solely on endometrial thickness measurements in perimenopausal patients. Abnormal echogenicity and texture are equally important indicators of underlying pathology. 1

Tissue Diagnosis: The Non-Negotiable Step

Endometrial sampling via office biopsy (Pipelle or Vabra device) is essential and should be performed liberally in perimenopausal women with abnormal bleeding. 2, 3 These devices have sensitivities of 99.6% and 97.1% respectively for detecting endometrial carcinoma. 2

When to Proceed Directly to Tissue Sampling

Perform endometrial biopsy when:

• Any thickened endometrium is visualized on TVUS
• Abnormal endometrial echogenicity or texture is present 1
• Bleeding persists despite negative initial imaging 1
• Patient has risk factors: obesity (BMI >30), prolonged unopposed estrogen exposure, nulliparity, Lynch syndrome family history 4, 2, 5

Critical caveat: Office endometrial biopsy has a false-negative rate of approximately 10%. 4, 3 If the patient remains symptomatic with a negative office biopsy, you must proceed to fractional dilation and curettage (D&C) under anesthesia. 4, 2, 3

Advanced Imaging: When and Why

Sonohysterography

Use saline infusion sonohysterography when TVUS demonstrates a focal endometrial abnormality to distinguish between polyps and submucosal leiomyomas (97% accuracy). 1 However, understand its critical limitation: sonohysterography cannot reliably distinguish benign endometrial pathology from endometrial cancer, so endometrial sampling or hysteroscopy remains mandatory when focal pathology is identified. 1

MRI Pelvis

Reserve MRI with gadolinium contrast (including diffusion-weighted sequences) for cases where:

• Initial ultrasound is inconclusive or technically inadequate 1
• The uterus is too large to fully visualize with TVUS 1
• You need to differentiate benign from malignant pathology (sensitivity 79%, specificity 89% for endometrial cancer) 1

MRI features most helpful for identifying malignancy include abnormal signal on diffusion-weighted imaging and irregularity of the endometrial-myometrial interface. 1

Hysteroscopy: The Definitive Diagnostic Tool

Hysteroscopy with directed biopsy should be performed when:

• Persistent or recurrent bleeding occurs despite negative initial workup 4, 3
• Focal lesions (polyps, submucosal myomas) are identified on imaging 1
• Office biopsy is negative but clinical suspicion remains high 6

Recent evidence (2026) demonstrates that hysteroscopy with visually directed biopsy provides superior diagnostic accuracy compared to blind endometrial sampling for detecting endometrial cancer, hyperplasia, polyps, and submucosal myomas. 6

Genetic Screening Considerations

Universal tumor testing for DNA mismatch repair (MMR) deficiency is recommended using immunohistochemistry for MLH1, MSH2, MSH6, and PMS2. 4, 3 If MLH1 loss is identified, test for promoter methylation to distinguish somatic from germline mutations. 4, 3 Women with Lynch syndrome have up to 60% lifetime risk of endometrial cancer. 4, 2, 5, 3

Algorithmic Approach Summary

1. Initial evaluation: TVUS + transabdominal ultrasound with Doppler
2. Immediate endometrial biopsy if: thickened endometrium, abnormal texture/echogenicity, or high-risk features present
3. If focal abnormality on TVUS: Add sonohysterography to characterize, then proceed to hysteroscopy with directed biopsy
4. If office biopsy negative but symptoms persist: Fractional D&C under anesthesia (mandatory)
5. If imaging inconclusive: MRI pelvis with contrast and diffusion-weighted sequences
6. If diagnosis confirmed: Universal MMR tumor testing

The bottom line: Imaging guides the approach, but tissue diagnosis through endometrial sampling is non-negotiable in perimenopausal women with abnormal bleeding. Never rely on imaging alone to exclude endometrial cancer in this population.